Study guide

11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

Key Takeaways Explain This Topic AI

Biomarkers of exposure quantify parent, metabolite, or adducts; biomarkers of effect show a biological alteration (for example cholinesterase inhibition); biomarkers of susceptibility are host factors such as enzyme polymorphisms.

Spot urine is often creatinine-adjusted to reduce hydration noise; reverse dosimetry converts a blood or urine concentration back to an estimated intake using excretion fraction, volume, or a PBPK model—not by treating the biomarker as already an RfD.

Persistence, bioavailability, bioaccumulation, and biomagnification are different fate processes; log Kow and Koc screen partitioning, and BCF is C_organism / C_water at steady state.

OECD 305 is the conceptual fish bioaccumulation test (aqueous BCF and, for poorly soluble substances, dietary biomagnification); sentinel species indicate contamination in the field.

Monte Carlo exposure assessment samples distributions of C, IR, BW, and other terms to produce a distribution of dose; it is a method for variability and uncertainty, not a software tutorial.

Last updated: September 2026

Internal dose is not the bottle concentration

Applied dose (what was in the chamber or the gavage needle) and potential dose (what contacted the skin or the GI lumen) are not internal dose (what reached blood or the target). Handbook III.B.2–4 asks you to reconstruct internal dose from biomarkers , to know which environmental fate processes change the concentration that ever reaches a receptor, and to use bioaccumulation metrics such as a bioconcentration factor (BCF) without confusing them with biomagnification. Independent ExamFinch teaching in this section covers those tools at a conceptual level. NHANES as a national public-health database is developed in the applied-toxicology chapter on environmental and public-health practice; here you only need to know how a urine or blood number becomes a dose. This material is not an ABT product and does not claim official approval, review, or partnership with ABT, CDC, OECD, or EPA.

Biomarkers of exposure, effect, and susceptibility

Biomarker of exposure. A chemical, metabolite, or adduct measured in a biological matrix that indicates contact: blood lead , urinary trichloroacetic acid after trichloroethylene, urinary cotinine after nicotine, hemoglobin adducts of ethylene oxide . These close the pathway in a CSM: if the metabolite is in urine, a complete path existed, even if the air model was uncertain. They still require the parent versus metabolite and unbound versus total discipline from section 11.1. A urinary metabolite is not parent air concentration.

Biomarker of effect. A measurable alteration in a biochemical, physiologic, or other process: red-cell acetylcholinesterase inhibition after an organophosphate, ALA dehydratase inhibition after lead, DNA strand breaks, heme-synthesis changes. Effect biomarkers sit closer to hazard and clinical toxicology. Using an effect biomarker as if it were a kilogram-per-day intake, without a calibration, mixes III.B with III.A.

Biomarker of susceptibility. A host factor that changes internal dose or response for the same applied exposure: GSTM1 deletion, PON1 status for some organophosphates, ALDH2*2 for acetaldehyde, age-related creatinine excretion, pregnancy-related plasma volume. Susceptibility biomarkers do not prove that exposure occurred; they change how a given exposure is read.

Class What it answers Teaching example

Exposure Was there contact, and how much chemical (or metabolite) is in the body? Blood lead; urinary metals; parent or metabolite in plasma

Effect Has a biological process already changed? AChE inhibition; ALA-D inhibition

Susceptibility Who, at the same external dose, is expected to differ? Metabolic polymorphisms; low creatinine excretion in a small child

Adducts can straddle exposure and effect: a hemoglobin adduct documents that reactive parent reached blood, and it is also a molecular alteration. On the examination, name the question the marker is being asked to answer.

From urine and blood to dose: creatinine and reverse dosimetry

Spot urine concentrations swing with hydration. Creatinine adjustment (µg/g creatinine) reduces that noise because creatinine excretion is more stable than water excretion in a given person, though it still varies with muscle mass, age, sex, and renal function. Specific gravity adjustment is the cousin used when creatinine is a poor denominator (very low muscle mass). 24-hour urine is the gold-volume method and is rare in population surveys.

A simple mass-balance reverse dosimetry (steady state, one-compartment teaching form) is:

Estimated daily intake ≈ (C_urine × V_urine) / F_excreted

or, with creatinine: (C_µg/g × creatinine excretion in g/day) / F_excreted , where F_excreted is the fraction of parent intake that appears as that analyte in urine. If F is 0.5, the urine amount is half the intake, so intake is twice the excreted mass. If you measured a metabolite , F must be the molar yield of that metabolite, not 1.0 by default. Blood reverse dosimetry usually needs clearance or a PBPK model: concentration = intake × bioavailability / clearance at steady state, rearranged for intake. Treating a µg/L blood number as if it were already an RfD in mg/kg-day skips every term in that rearrangement.

NHANES , run by CDC, is the later-chapter survey that reports nationally representative blood and urine concentrations for many environmental chemicals. Use it here only as the reason those creatinine-adjusted tables exist: they are biomarker distributions , not ready-made ADDs. Converting an NHANES 95th percentile urine value into a population intake is reverse dosimetry plus survey weights, not a lookup of the RfD.

Fate and transport: four words that are not synonyms

Persistence. How long the parent remains in a medium (hydrolysis, photolysis, biodegradation half-lives). A short air half-life can coexist with a long sediment half-life.

Bioavailability. The fraction of contacted mass that is absorbed. Soil lead phosphate is less bioavailable than lead acetate in water; a total-soil milligram is not an absorbed milligram.

Bioaccumulation. Net uptake into an organism from all routes (water, diet, sediment, air) relative to the surrounding medium. Bioconcentration is the water-only subset (dissolved chemical across the gill, in the OECD 305 aqueous design).

Biomagnification. Concentration increases with trophic level in a food web (classic organochlorines in piscivorous birds). High BCF does not automatically prove biomagnification if the chemical is metabolized in the predator or is not transferred in diet.

log Kow (octanol–water partition coefficient) screens hydrophobicity. Very low log Kow: stays in water, little lipid storage. Mid-range (often cited around 3–6): bioaccumulation concern. Very high log Kow (often >6): uptake can fall because of reduced bioavailability, size, or metabolism—the “superhydrophobic” caveat, not a safety certificate.

Koc (organic-carbon–water partition coefficient) describes sorption to soil and sediment organic carbon. Kd = Koc × foc . High Koc means the chemical rides organic carbon: less in the dissolved water column, more in sediment and in soil that children ingest. Dissolved-water BCFs can look modest while benthic receptors still see a sediment path.

BCF, OECD 305, and sentinels

BCF = C_organism / C_water at steady state, typically L/kg on a whole-fish wet-weight basis. OECD Test Guideline 305 is the conceptual fish test: aqueous exposure to measure BCF (uptake rate k1 and depuration k2, with BCF ≈ k1/k2), and a dietary exposure design for poorly water-soluble substances that reports a biomagnification factor (BMF) from spiked feed. It is not a mammalian TK study and not a human biomonitoring protocol.

Regulatory flags differ by program; do not memorize one number as universal. Many TSCA -style PBT discussions treat BCF/BAF of 1,000 as bioaccumulative and 5,000 as very bioaccumulative. REACH Annex XIII uses 2,000 (B) and 5,000 (vB). Read the statute you are actually in. A BCF is still not a human ADD.

Sentinel species are organisms whose tissue or health signals contamination for a media or food web: historically canaries in mines; mussels in coastal monitoring; piscivorous birds for persistent organochlorines; lichens for atmospheric metals. A sentinel documents that a pathway is complete in the field. It does not replace a human CSM, and a clean sentinel in the wrong habitat does not clear a different receptor.

Monte Carlo / probabilistic exposure (method, not software)

Point-estimate ADD uses one C, one IR, one BW. Probabilistic exposure draws those inputs from distributions (for example lognormal concentration, normal body weight, triangular or empirical intake rate), computes ADD thousands of times, and reports a distribution of dose—median, mean, 95th percentile—plus sensitivity (which input drives the variance). That is Monte Carlo sampling. It does not require naming a commercial package. It does not fix a wrong CSM: sampling an incomplete pathway still yields a precise estimate of a dose that does not occur. It is also not a substitute for a PBPK reverse-dosimetry model; it is a way to propagate variability and uncertainty through the same equation taught in section 11.2. EPA RAGS Volume III is the Superfund-language cousin of this idea. On the examination, know what the output is (a dose distribution) and what it is not (proof that the 95th percentile equals the RME point estimate, or a license to ignore correlation between body weight and intake).

Scenario

A community has blood lead measurements, soil lead, and a fish advisory. Blood lead is a biomarker of exposure (and, at high levels, sits next to effect markers such as ALA-D). Converting the geometric mean blood lead to an incremental soil intake requires a biokinetic model (IEUBK-style thinking), not dividing µg/dL by 70 kg. Urinary creatinine-adjusted cadmium in NHANES tables is not an RfD; reverse dosimetry would need excretion fraction and an intake reconstruction, then comparison with a toxicity value in matching units. Fish-tissue concentrations in a piscivorous bird are a sentinel/food-web signal of biomagnification for a persistent organochlorine; the human subsistence-fisher ADD still needs a consumption rate × fillet concentration , which is dietary exposure, not a BCF. Running Monte Carlo on IR and BW while leaving C as a single maximum detection in an unused well produces a tight distribution of a pathway the CSM already ruled incomplete.

Traps

Calling AChE inhibition a biomarker of exposure, or GSTM1 genotype proof that exposure occurred.

Treating µg/g creatinine as mg/kg-day without reverse dosimetry.

Equating BCF with biomagnification, or OECD 305 with a human urine study.

Using log Kow as if it were Koc, or dissolved BCF as if sediment were irrelevant.

Treating a Monte Carlo 95th percentile as automatically equal to a RAGS RME point estimate, or as a reason to skip the CSM.